- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02308553
Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma (NIPAWILMA)
Phase I/II,Multicenter,Randomized,Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Phase I: Run-In-Phase Based on acceptable safety data for nintedanib monotherapy, a rapid dose finding will be conducted in a classical 3+3 design. Predefined dose levels are 150 mg (dose level 1) and 200 mg (dose level 2) nintedanib, twice daily, with weekly paclitaxel 90 mg/m2.
Study Phase II Patients with advanced (unresectable Stage III or IV) BRaf V600 wild type melanoma (n=120) will be randomized (1:1) to receive either Nintedanib (150 or 200 mg BID depending on results of phase I) in combination with paclitaxel or Placebo in combination with paclitaxel.
Total study duration per patient: approximately 12 months of therapy + Follow up until end of study
All patients enrolled in either phase I or phase II will be treated according to the following treatment plan:
Week 1 - 24:
Chemotherapy with paclitaxel combined with nintedanib/placebo
Week 25 - 48:
Extended monotherapy with nintedanib/placebo
Week 52 (or approximately 4 weeks after last treatment dose):
End of Treatment visit
Follow up:
After end of treatment the survival, disease status and further therapies of each patient will be assessed every 3 months until death, progression of disease or end of study whichever occurs first
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Buxtehude, Germany, 21614
- Elbeklinikum Buxtehude
-
Gera, Germany, 07548
- SRH Wald-Klinikum Gera
-
Heidelberg, Germany, 69120
- National Centre for Tumour Diseases (NCT)
-
Homburg, Germany, 66421
- Universitätsklinikum des Saarlandes
-
Ludwigshafen, Germany, 67063
- Klinikum der Stadt Ludwigshafen am Rhein gGmbH
-
Lübeck, Germany, 23538
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck
-
München, Germany, 80337
- University Hospital München
-
Münster, Germany, 48149
- University Hospital Münster
-
Münster, Germany, 48157
- Fachklinik Hornheide
-
-
NRW
-
Essen, NRW, Germany, 45147
- University Hospital Essen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed, (surgically incurable or unresectable) stage III or IV, BRAF V600 wildtype metastatic cutaneous malignant melanoma.
- Written informed consent
- A minimum of 1 measurable lesion according to RECIST v1.1 criteria.
- ECOG of 0-1.
Adequate hematologic, renal and liver function within 14 days prior to initiation of dosing:
Hematologic:
- Absolute neutrophil count (ANC) ≥1.5 x 109/L
- Hemoglobin ≥ 9 g/dL (5.6 mmol/L; Subjects may not have had a transfusion within 7 days of screening assessment)
- Platelets: ≥ 100 x 109/L
Hepatic
- Total bilirubin: ≤ 1.0 x ULN
- AST and ALT: ≤ 1.5 x ULN (In the case of liver metastases: 2.5 x ULN)
- Renal o Serum creatinine: ≤ 1.5 mg/dL (133 µmol/L) or, if greater than 1.5 mg/dL: Calculated creatinine clearance: ≥ 50 mL/min
- effective method of contraception for at least 3 months after completion of nintedanib/placebo monotherapy as directed by their physician.
- Men should use an effective method of contraception during treatment and for at least 6 months after completion of paclitaxel treatment and for at least 3 months after completion of nintedanib/placebo monotherapy as directed by their physician.
- Patients must have recovered from all prior treatment-related toxicities to NCI CTCAE (v4.0) Grade of 0 or 1, except for toxicities not considered a safety risk such as alopecia.
- Male or female, aged 18 years or older
- Life expectancy at least 3 months
Exclusion Criteria:
- Prior systemic therapy with taxanes or kinase inhibitors. Any prior therapy for metastatic disease must have been discontinued at least 4 weeks prior to initiation of dosing.
- Major surgery or radiation therapy within 4 weeks of starting the study treatment (minor surgical procedures such as biopsies are allowed, however patients must have recovered).
Known inherited predisposition to bleeding or thrombosis and therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325mg per day)
Patients with the following coagulation parameters will be excluded:
- International normalised ratio (INR) > 2
- Prothrombin time (PT) and partial thromboplastin time (PTT): > 50% of deviation of institutional ULN
- History of clinically significant haemorrhagic or thromboembolic event in the past 6 months
- NCI CTCAE (V4.0) grade 3 hemorrhage within 4 weeks of starting the study treatment.
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to randomization.
- Serious, non-healing wound, ulcer, or bone fracture.
Known CNS disease:
- Previous Grade 2 or higher sensory neuropathy.
- History of or known spinal cord compression, or carcinomatous meningitis, or evidence of active brain metastases (e.g. stable for <4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomization) or leptomeningeal disease on screening CT or MRI scan.
- Any of the following within the 6 months prior to enrolment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
- New York Heart Association (NYHA) Grade II or greater congestive heart failure.
- Ongoing cardiac dysrhythmias of NCI CTCAE Version 4.0 grade ≥ 2.
- Inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications).
- Symptomatic peripheral vascular disease.
- Proteinuria at screening as demonstrated by urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).
- Known hypersensitivity reaction to any of the components of study treatment (e.g. contrast media) or other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
- Previous cancer (unless a RFS interval of at least 5 years) with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin.
- Known clinically uncontrolled infectious disease including HIV positivity or AIDS-related illness and active or chronic hepatitis C and/or B infection.
- Pregnancy (absence to be confirmed by ß-hCG test) or lactation period.
- Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
- Active alcohol or drug abuse
- Treatment with other investigational drugs or treatments in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial.
- Legal incapacity or limited legal capacity
- Significant weight loss (> 10% of body weight) within past 6 months prior to inclusion into the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nintedanib + Paclitaxel
Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
|
Nintedanib (150 mg or 200 mg BID)
Other Names:
Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
Other Names:
|
Placebo Comparator: Nintedanib-Placebo + Paclitaxel
Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
|
Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
Other Names:
Placebo (150 mg or 200 mg BID)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression-free survival (PFS)
Time Frame: 12 months after LPI
|
Time from administration of first study drug to the date of first documented progression or death due to any cause, whichever occurs first
|
12 months after LPI
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 12 months after LPI
|
Time from the date of first administration of study drug to the date of death due to any cause.
|
12 months after LPI
|
Safety and toxicity (graded according to CTCAE, Version 4.0)
Time Frame: 12 months after LPI
|
Reporting of adverse events from the date of first administration of study drug until 30 days after last administration of study drug
|
12 months after LPI
|
Quality of Life (EORTC QLQ-C30)
Time Frame: 12 months after LPI
|
Quality of life during therapy (i.e. until end of treatment visit)
|
12 months after LPI
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dirk Schadendorf, Prof. Dr., University Hospital, Essen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Protein Kinase Inhibitors
- Paclitaxel
- Nintedanib
Other Study ID Numbers
- Nipawilma_2013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Malignant Melanoma
-
National Cancer Institute (NCI)Active, not recruitingStage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
National Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8United States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...United States, Canada, Ireland
-
National Cancer Institute (NCI)Active, not recruitingUnresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8United States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the BrainUnited States
-
Catalysis SLCompletedCutaneous Melanoma, Stage II | Cutaneous Melanoma, Stage III | Malignant Cutaneous MelanomaCuba
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Cutaneous MelanomaUnited States
Clinical Trials on Nintedanib
-
Boehringer IngelheimCompletedCarcinoma, HepatocellularJapan
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedHealthyUnited Kingdom
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruiting
-
Wake Forest University Health SciencesBoehringer IngelheimTerminated
-
Boehringer IngelheimCompletedIdiopathic Pulmonary FibrosisSpain, Korea, Republic of, Belgium, Czechia, Australia, Germany, United Kingdom, United States, France, Finland, Japan, Poland, Hungary
-
Boehringer IngelheimApproved for marketingIdiopathic Pulmonary FibrosisUnited States
-
Boehringer IngelheimActive, not recruitingLung Diseases, InterstitialUnited States, Spain, United Kingdom, Canada, Finland, Norway, Italy, Argentina, Belgium, Brazil, Czechia, France, Greece, Mexico, Poland, Germany, Portugal
-
Boehringer IngelheimNo longer availableLung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
-
Boehringer IngelheimNo longer availableIdiopathic Pulmonary FibrosisBrazil